Expansion Opportunity Agno Pharma is actively expanding its U.S. footprint and has recent partnerships and acquisitions that broaden its manufacturing capabilities, creating cross-sell opportunities for high-potency APIs, sterile products, and complex injectables to existing and new customers in North America.

Strategic Acquisitions The acquisition of Actylis Cascade Chemistry assets and the Lubrizol Particle Sciences acquisition position Agno as a broader CDMO with enhanced API development and manufacturing capacity, enabling targeted pitches to biotech and generics players seeking integrated development-to-commercialization solutions.

Partnership Potential Recent partnerships with Particlesciences and SiCare Bio indicate a willingness to collaborate on drug formulation platforms and advanced delivery systems, suggesting cross-sell of formulation services, sterile platforms, and complex injectable technologies to pharmaceutical and biotech customers.

Global Reach With a track record serving North America and Europe and a growing U.S. presence, Agno can offer geographically diverse manufacturing and regulatory-compliant CDMO services, appealing to multinational clients seeking global supply chain resilience for APIs, sterile products, and cGMP manufacturing.

Capabilities Fit Agno's capabilities in sterile APIs, highly potent APIs, sterile drug product formulations, and drug product formulation R&D align with customers pursuing end-to-end development-to-commercialization solutions, presenting upsell opportunities for full-service partnerships and long-term contracts.